Add Yahoo as a preferred source to see more of our stories on Google. Oct. 31—(StatePoint) November is Pulmonary Hypertension Awareness Month, and the American Lung Association, with support from ...

A wireless implantable device that remotely monitors pulmonary artery pressure offers reliable safety and is linked to a significant reduction in the risk for heart failure-related hospitalisation.

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection ...

New findings reveal pulmonary arterial hypertension may affect the brain early. Learn how inflammation and cognitive decline ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted premarket approval to Endotronix’s pulmonary artery sensor platform for remote management of ...

Please provide your email address to receive an email when new articles are posted on . Engagement in daily pulmonary artery pressure readings may benefit patients with heart failure. Patients made ...

In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this report, we follow up on what has happened since. After the FDA approved both ...

Panelists discuss how managing patients with comorbidities requires careful evaluation to distinguish true Group 1 PAH features from underlying cardiac or pulmonary disease, with a more measured ...